Arrowhead Research | ARWR - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
Alnylam Pharmaceuticals USD 898.54M 66.78M 2026-03
Anika Therapeutics USD 133.9M 103.93M 2026-03
Arrowhead Research USD 215M 8.23M 2026-03
Heron Therapeutics USD 40.55M 1.46M 2025-12
Incyte USD 5.62B 4.5B 2026-03
Ionis Pharmaceuticals USD 364M 54M 2026-03
Ligand Pharmaceuticals USD 34.35M 5.27M 2026-03
Merck USD 18.17B 8.01B 2026-03
Moderna USD 1.78B 242M 2026-03
Nektar Therapeutics USD 40.9M 44.19M 2025-12
Novartis USD 9.29B 507M 2026-03
Sarepta Therapeutics USD 372.37M 480.65M 2026-03
TG Therapeutics USD 170.12M 28.04M 2026-03
Ultragenyx Pharmaceutical USD 305M 16M 2026-03
Vertex Pharmaceuticals USD 1.85B 78.6M 2026-03
Xencor USD 82.38M 513K 2026-03